PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

Publication date: November 2012
Report size: 84 pages

Keywords : rheumatoid arthritis, arthritis, Pathology

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

Summary

GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Indian physicians included in our study typically follow guidelines such as ACR or EULAR, but also follow their own clinical experience. In India, the process to diagnosis a patient with RA usually begins with the PCP or GP regardless of which potential stage the patient is in, then progresses with the referral to a rheumatologist for further diagnosis and treatment as this occurs about 32% of the time. Also, most people seeking treatment are within the 35-55-year-old group. Within this age group, females and males are equally distributed according to our physician experts.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2011 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in India
- Obtain sales forecast from 2011-2022 in India

Pathology Industry in India

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 13
3.1.4 Quality of Life 13
3.2 Symptoms 14
4 Disease Management 15
4.1 Treatment Overview 18
4.2 India 22
4.2.1 Diagnosis 22
4.2.2 Clinical Practice 22
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 24
5.3 Product Profiles - Major Brands 26
5.3.1 Enbrel (etanercept) 26
5.3.2 Remicade (infliximab) 32
5.3.3 Orencia (abatacept) 36
5.3.4 Actemra/RoActemra (tocilizumab) 40
5.3.5 Rituxan/MabThera (rituximab) 44
5.3.6 Methotrexate Sodium (numerous generic names) 48
5.3.7 DMARDs 51
6 Opportunity and Unmet Need 52
6.1 Overview 52
6.2 Unmet Needs 53
6.2.1 More rheumatologists in the field and physician knowledge of the disease 53
6.2.2 More cost-effective therapies through oral formulation and biosimilars 53
6.2.3 The development of predictive tests and discovery of biomarkers 54
6.2.4 The discovery of curative therapies 54
6.2.5 Improved drug safety and efficacy profiles 54
6.3 Gap Analysis 55
6.4 Opportunities 56
6.4.1 Predictive tools for diagnosis and treatment 56
6.4.2 Target specificity 56
7 Pipeline Assessment 57
7.1 Overview 57
7.2 Promising Drugs in Clinical Development 58
8 Market Outlook 60
8.1 India 60
8.1.1 Forecast 60
8.1.2 Key Events 62
8.1.3 Drivers and Barriers 63
9 Appendix 65
9.1 Abbreviations 65
9.2 Bibliography 67
9.3 Methodology 73
9.4 Forecasting Methodology 73
9.4.1 Diagnosed Rheumatoid Arthritis Patients 73
9.4.2 Percent Drug-treated Patients 74
9.4.3 Drugs Included in Each Therapeutic Class 74
9.4.4 Launch and Patent Expiry Dates 75
9.4.5 General Pricing Assumptions 75
9.4.6 Individual Drug Assumptions 76
9.4.7 Generic Erosion 80
9.4.8 Pricing of Pipeline agents 80
9.5 Physicians and Specialists Included in this Study 81
9.6 Primary Research - Prescriber Survey 81
9.7 About the Authors 82
9.7.1 Analysts 82
9.7.2 Global Head of Healthcare 83
9.8 About GlobalData 84
9.9 Contact Us 84
9.10 Disclaimer 84

List of Tables

Table 1: Symptoms of Rheumatoid Arthritis 14
Table 2: Treatment Guidelines for Rheumatoid Arthritis 18
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 21
Table 4: Treatment Guidelines for Rheumatoid Arthritis 25
Table 5: Product Profile - Enbrel 27
Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers 28
Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall 29
Table 8: Enbrel SWOT Analysis, 2012 31
Table 9: Product Profile - Remicade 33
Table 10: Remicade SWOT Analysis, 2012 35
Table 11: Product Profile - Orencia 37
Table 12: Orencia SWOT Analysis, 2012 39
Table 13: Product Profile - Actemra/RoActemra 41
Table 14: Actemra/RoActemra SWOT Analysis, 2012 43
Table 15: Product Profile - Rituxan 45
Table 16: Rituxan SWOT Analysis, 2012 47
Table 17: Product Profile - Methotrexate 49
Table 18: Methotrexate SWOT Analysis, 2012 50
Table 19: Summary of Minor Therapeutic Classes, 2012 51
Table 20: Overall Unmet Needs - Current Level of Attainment 52
Table 21: Clinical Unmet Needs - Gap Analysis, 2012 56
Table 22: Rheumatoid Arthritis - Phase Pipeline, 2012 58
Table 23: Sales Forecasts ($m) for Rheumatoid Arthritis in India 61
Table 24: Key Events Impacting Sales for Rheumatoid Arthritis in India, 2012 62
Table 25: Rheumatoid Arthritis Market - Drivers and Barriers in India, 2012 63
Table 26: Key Launch Dates 75
Table 27: Key Patent Expiries 75
Table 28: Physicians Surveyed, By Country 81

List of Figures

Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 10
Figure 2: Rheumatoid Arthritis Biologic Drug Targets 12
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System 17
Figure 4: Severity of Rheumatoid Arthritis 17
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations* 20
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 59
Figure 7: Sales for Rheumatoid Arthritis in India by Drug Class 61

Musculoskeletal Disorder in India